Bioaffinity Technologies Warrant Stock Net Income

BIAFW Stock  USD 0.60  0.03  5.26%   
bioAffinity Technologies Warrant fundamentals help investors to digest information that contributes to BioAffinity Technologies' financial success or failures. It also enables traders to predict the movement of BioAffinity Stock. The fundamental analysis module provides a way to measure BioAffinity Technologies' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioAffinity Technologies stock.
Last ReportedProjected for Next Year
Net Loss-7.9 M-8.3 M
Net Loss-7.2 M-7.6 M
Net Loss(0.91)(0.95)
Net Income Per E B T 1.00  0.80 
Net Loss is likely to drop to about (8.3 M) in 2024. Net Loss is likely to drop to about (7.6 M) in 2024.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

bioAffinity Technologies Warrant Company Net Income Analysis

BioAffinity Technologies' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

More About Net Income | All Equity Analysis

Current BioAffinity Technologies Net Income

    
  (7.94 M)  
Most of BioAffinity Technologies' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, bioAffinity Technologies Warrant is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

BioAffinity Net Income Driver Correlations

Understanding the fundamental principles of building solid financial models for BioAffinity Technologies is extremely important. It helps to project a fair market value of BioAffinity Stock properly, considering its historical fundamentals such as Net Income. Since BioAffinity Technologies' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of BioAffinity Technologies' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of BioAffinity Technologies' interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition

BioAffinity Accumulated Other Comprehensive Income

Accumulated Other Comprehensive Income

(3.82 Million)

BioAffinity Technologies reported Accumulated Other Comprehensive Income of (3.64 Million) in 2023
Based on the recorded statements, bioAffinity Technologies Warrant reported net income of (7.94 Million). This is 102.33% lower than that of the Biotechnology sector and 104.58% lower than that of the Health Care industry. The net income for all United States stocks is 101.39% higher than that of the company.

BioAffinity Net Income Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioAffinity Technologies' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioAffinity Technologies could also be used in its relative valuation, which is a method of valuing BioAffinity Technologies by comparing valuation metrics of similar companies.
BioAffinity Technologies is currently under evaluation in net income category among its peers.

BioAffinity Fundamentals

About BioAffinity Technologies Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze bioAffinity Technologies Warrant's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioAffinity Technologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of bioAffinity Technologies Warrant based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BioAffinity Stock Analysis

When running BioAffinity Technologies' price analysis, check to measure BioAffinity Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAffinity Technologies is operating at the current time. Most of BioAffinity Technologies' value examination focuses on studying past and present price action to predict the probability of BioAffinity Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAffinity Technologies' price. Additionally, you may evaluate how the addition of BioAffinity Technologies to your portfolios can decrease your overall portfolio volatility.